Lunai Bioworks Inc. (NASDAQ:LNAI) Short Interest Down 47.7% in June

Lunai Bioworks Inc. (NASDAQ:LNAI) was the recipient of a large drop in short interest in the month of June. As of June 30th, there was short interest totaling 150,195 shares, a drop of 47.7% from the June 15th total of 287,256 shares. Based on an average daily volume of 4,793,299 shares, the short-interest ratio is currently 0.0 days. Approximately 3.3% of the company’s shares are short sold.

Hedge Funds Weigh In On Lunai Bioworks

A hedge fund recently bought a new position in Lunai Bioworks stock. Millennium Management LLC purchased a new position in shares of Lunai Bioworks Inc. (NASDAQ:LNAI) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 202,629 shares of the company’s stock, valued at approximately $288,000. Millennium Management LLC owned about 0.87% of Lunai Bioworks as of its most recent SEC filing. Hedge funds and other institutional investors own 71.41% of the company’s stock.

Lunai Bioworks Stock Down 0.8%

Shares of Lunai Bioworks stock traded down $0.03 on Wednesday, hitting $2.96. 7,300 shares of the company traded hands, compared to its average volume of 1,657,578. Lunai Bioworks has a 12-month low of $1.21 and a 12-month high of $28.80. The company has a market cap of $13.40 million, a PE ratio of -7.39 and a beta of 0.37. The company has a 50-day moving average price of $2.82 and a 200 day moving average price of $3.98.

Lunai Bioworks (NASDAQ:LNAI) last issued its earnings results on Friday, May 15th. The company reported ($0.10) EPS for the quarter. The business had revenue of $0.02 million during the quarter.

Analysts Set New Price Targets

A number of analysts have recently issued reports on LNAI shares. Wall Street Zen upgraded Lunai Bioworks to a “sell” rating in a report on Saturday, May 23rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Lunai Bioworks in a report on Wednesday, July 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

About Lunai Bioworks

Enochian Biosciences, Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection.